Prospective randomised clinical trials are needed to evaluate the effects of IL-6R inhibition on glycaemic indices, insulin sensitivity and pancreatic β cell function in patients with comorbid RA and diabetes and determine the clinical relevance of differences in IL-6R, IL-1β and TNF inhibition. This evidence concerns the gene INS and diabetes mellitus.